Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rough Patch For Lupin, Much Riding On Solosec, Enbrel Biosimilar

Executive Summary

An under pressure US business dented Lupin in Q1, with a recovery seen only in the second half of FY19 as new generic products roll out. A ramp-up in on-market products like Solosec in the US and a smooth run to launch for biosimilar Enbrel in Japan and the EU, among other products, could be vital to restore momentum for the Indian firm.

Advertisement

Related Content

Lupin Paints Better Second Half Riding On Solosec, New US Launch Hopes
FDA Clears Lupin API Site Of NDMA Risk, Compliance Efforts Ongoing
Perrigo Generic Of Teva's ProAir Stunned By Another FDA CRL
Lupin-Yoshindo Stake Claim For Play In Japan Biosimilar Enbrel Market
Lupin Primes For Specialty Future With Symbiomix Acquisition

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123571

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel